Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

MedChem/Life Medical

This article was originally published in The Gray Sheet

  • News

Executive Summary

MedChem Products signs letter of intent to buy the assets and technology of the Sure-Closure skin stretching product line from Life Medical Sciences for $4 mil. in cash, a $500,000 interest free loan and a 10% royalty on the worldwide sales of Sure-Closure devices for the next 10 years. MedChem plans to combine its 21 Avitene microfibrillar collagen hemostat sales people with Life Medical's 24 sales reps into a single sales force. In addition, "several members" of management at Life Medical Sciences will join MedChem after the deal is closed, including LMS President and CEO Edward Quilty. Quilty replaces James Marten as MedChem President and CEO. Marten will continue as the company's chairman of the board. Life Medical says the Sure-Closure sale will enable the firm to focus on its Cariel wound healing gel technology, which entered Phase II/III trials in Europe in April 1994

Table

View full table

Tags:
Latest Headlines

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

See All
UsernamePublicRestriction

Register

MT002585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By